1.Long-term results of forward intensity-modulated radiation therapy for patients with early-stage breast cancer.
Boram HA ; Hyun Suk SUH ; Jihae LEE ; Kyung Ja LEE ; Rena LEE ; Byung In MOON
Radiation Oncology Journal 2013;31(4):191-198
PURPOSE: To observe long-term clinical outcomes for patients with early-stage breast cancer treated with forward intensity-modulated radiation therapy (IMRT), including local control and clinical toxicities. MATERIALS AND METHODS: We retrospectively analyzed a total of 214 patients with stage I-II breast cancer who were treated with breast conserving surgery followed by adjuvant breast radiation therapy between 2001 and 2008. All patients were treated using forward IMRT. The whole breast was irradiated to a dose of 50 to 50.4 Gy followed by an 8 to 12 Gy electron boost to the surgical bed. RESULTS: The median age was 46 years (range, 21 to 82 years) and the medial follow-up time was 7.3 years (range, 2.4 to 11.7 years). Stage T1 was 139 (65%) and T2 was 75 (35%), respectively. Ipsilateral breast recurrence was observed in 3 patients. The 5- and 10-year local control rates were 99.1% and 97.8%, respectively. The cosmetic outcome was evaluated according to the Harvard scale and 89.4% of patients were scored as excellent or good. CONCLUSION: The whole breast radiation therapy as an adjuvant treatment using a forward IMRT technique showed excellent long-term local control as well as favorable outcomes of toxicity and cosmesis.
Breast Neoplasms*
;
Breast*
;
Follow-Up Studies
;
Humans
;
Mastectomy, Segmental
;
Recurrence
;
Retrospective Studies
2.A Case Report of Extramedullary Myeloma Mimicking Lymphoma with Extensive Abdominal Involvement
Jihae MOON ; Jeong Ah HWANG ; Hyeong Cheol SHIN ; Seung Soo KIM ; Ji Hye LEE ; Ji Eun LEE ; Seo Youn CHOI ; Min Young LEE
Journal of the Korean Radiological Society 2019;80(5):997-1002
Extramedullary myeloma refers to the presence of myeloma deposits outside the skeletal system and typically indicates a poor prognosis associated with shorter overall survival and progression- free survival. We report a case of extramedullary myeloma with extensive, abdominal multi-organ involvement mimicking lymphoma at initial diagnosis. Bulky retroperitoneal masses with severe diffusion restriction and patency of encased vessels can be MR findings of both myeloma and lymphoma. Radiologic findings such as arterial hyperenhancement, obstructive uropathy, and the lack of associated lymphadenopathy may favor a diagnosis of myeloma over lymphoma.
3.Treatment outcomes after adjuvant radiotherapy following surgery for patients with stage I endometrial cancer.
Jiyoung KIM ; Kyung Ja LEE ; Kyung Ran PARK ; Boram HA ; Yi Jun KIM ; Wonguen JUNG ; Rena LEE ; Seung Cheol KIM ; Hye Sung MOON ; Woong JU ; Yun Hwan KIM ; Jihae LEE
Radiation Oncology Journal 2016;34(4):265-272
PURPOSE: The purpose of this study is to evaluate the treatment outcomes of adjuvant radiotherapy using vaginal brachytherapy (VB) with a lower dose per fraction and/or external beam radiotherapy (EBRT) following surgery for patients with stage I endometrial carcinoma. MATERIALS AND METHODS: The subjects were 43 patients with the International Federation of Gynecology and Obstetrics (FIGO) stage I endometrial cancer who underwent adjuvant radiotherapy following surgery between March 2000 and April 2014. Of these, 25 received postoperative VB alone, while 18 received postoperative EBRT to the whole pelvis; 3 of these were treated with EBRT plus VB. The median EBRT dose was 50.0 Gy (45.0–50.4 Gy) and the VB dose was 24 Gy in 6 fractions. Tumor dose was prescribed at a depth of 5 mm from the cylinder surface and delivered twice per week. RESULTS: The median follow-up period for all patients was 57 months (range, 9 to 188 months). Five-year disease-free survival (DFS) and overall survival (OS) for all patients were 92.5% and 95.3%, respectively. Adjuvant radiotherapy was performed according to risk factors and stage IB, grade 3 and lymphovascular invasion were observed more frequently in the EBRT group. Five-year DFS for EBRT and VB alone were 88.1% and 96.0%, respectively (p = 0.42), and 5-year OS for EBRT and VB alone were 94.4% and 96%, respectively (p = 0.38). There was no locoregional recurrence in any patient. Two patients who received EBRT and 1 patient who received VB alone developed distant metastatic disease. Two patients who received EBRT had severe complications, one each of grade 3 gastrointestinal complication and pelvic bone insufficiency fracture. CONCLUSION: Adjuvant radiotherapy achieved high DFS and OS with acceptable toxicity in stage I endometrial cancer. VB (with a lower dose per fraction) may be a viable option for selected patients with early-stage endometrial cancer following surgery.
Brachytherapy
;
Disease-Free Survival
;
Endometrial Neoplasms*
;
Female
;
Follow-Up Studies
;
Fractures, Stress
;
Gynecology
;
Humans
;
Obstetrics
;
Pelvic Bones
;
Pelvis
;
Radiotherapy
;
Radiotherapy, Adjuvant*
;
Radiotherapy, Conformal
;
Recurrence
;
Risk Factors
4.Prognostic analysis of uterine cervical cancer treated with postoperative radiotherapy: importance of positive or close parametrial resection margin.
Yi Jun KIM ; Kyung Ja LEE ; Kyung Ran PARK ; Jiyoung KIM ; Wonguen JUNG ; Rena LEE ; Seung Cheol KIM ; Hye Sung MOON ; Woong JU ; Yun Hwan KIM ; Jihae LEE
Radiation Oncology Journal 2015;33(2):109-116
PURPOSE: To analyze prognostic factors for locoregional recurrence (LRR), distant metastasis (DM), and overall survival (OS) in cervical cancer patients who underwent radical hysterectomy followed by postoperative radiotherapy (PORT) in a single institute. MATERIALS AND METHODS: Clinicopathologic data of 135 patients with clinical stage IA2 to IIA2 cervical cancer treated with PORT from 2001 to 2012 were reviewed, retrospectively. Postoperative parametrial resection margin (PRM) and vaginal resection margin (VRM) were investigated separately. The median treatment dosage of external beam radiotherapy (EBRT) to the whole pelvis was 50.4 Gy in 1.8 Gy/fraction. High-dose-rate vaginal brachytherapy after EBRT was given to patients with positive or close VRMs. Concurrent platinum-based chemoradiotherapy (CCRT) was administered to 73 patients with positive resection margin, lymph node (LN) metastasis, or direct extension of parametrium. Kaplan-Meier method and log-rank test were used for analyzing LRR, DM, and OS; Cox regression was applied to analyze prognostic factors. RESULTS: The 5-year disease-free survival was 79% and 5-year OS was 91%. In univariate analysis, positive or close PRM, LN metastasis, direct extension of parametrium, lymphovascular invasion, histology of adenocarcinoma, and chemotherapy were related with more DM and poor OS. In multivariate analysis, PRM and LN metastasis remained independent prognostic factors for OS. CONCLUSION: PORT after radical hysterectomy in uterine cervical cancer showed excellent OS in this study. Positive or close PRM after radical hysterectomy in uterine cervical cancer correlates with poor prognosis even with CCRT. Therefore, additional treatments to improve local control such as radiation boosting need to be considered.
Adenocarcinoma
;
Brachytherapy
;
Chemoradiotherapy
;
Disease-Free Survival
;
Drug Therapy
;
Humans
;
Hysterectomy
;
Lymph Nodes
;
Multivariate Analysis
;
Neoplasm Metastasis
;
Pelvis
;
Prognosis
;
Radiotherapy*
;
Recurrence
;
Retrospective Studies
;
Uterine Cervical Neoplasms*
5.Prognostic analysis of uterine cervical cancer treated with postoperative radiotherapy: importance of positive or close parametrial resection margin.
Yi Jun KIM ; Kyung Ja LEE ; Kyung Ran PARK ; Jiyoung KIM ; Wonguen JUNG ; Rena LEE ; Seung Cheol KIM ; Hye Sung MOON ; Woong JU ; Yun Hwan KIM ; Jihae LEE
Radiation Oncology Journal 2015;33(2):109-116
PURPOSE: To analyze prognostic factors for locoregional recurrence (LRR), distant metastasis (DM), and overall survival (OS) in cervical cancer patients who underwent radical hysterectomy followed by postoperative radiotherapy (PORT) in a single institute. MATERIALS AND METHODS: Clinicopathologic data of 135 patients with clinical stage IA2 to IIA2 cervical cancer treated with PORT from 2001 to 2012 were reviewed, retrospectively. Postoperative parametrial resection margin (PRM) and vaginal resection margin (VRM) were investigated separately. The median treatment dosage of external beam radiotherapy (EBRT) to the whole pelvis was 50.4 Gy in 1.8 Gy/fraction. High-dose-rate vaginal brachytherapy after EBRT was given to patients with positive or close VRMs. Concurrent platinum-based chemoradiotherapy (CCRT) was administered to 73 patients with positive resection margin, lymph node (LN) metastasis, or direct extension of parametrium. Kaplan-Meier method and log-rank test were used for analyzing LRR, DM, and OS; Cox regression was applied to analyze prognostic factors. RESULTS: The 5-year disease-free survival was 79% and 5-year OS was 91%. In univariate analysis, positive or close PRM, LN metastasis, direct extension of parametrium, lymphovascular invasion, histology of adenocarcinoma, and chemotherapy were related with more DM and poor OS. In multivariate analysis, PRM and LN metastasis remained independent prognostic factors for OS. CONCLUSION: PORT after radical hysterectomy in uterine cervical cancer showed excellent OS in this study. Positive or close PRM after radical hysterectomy in uterine cervical cancer correlates with poor prognosis even with CCRT. Therefore, additional treatments to improve local control such as radiation boosting need to be considered.
Adenocarcinoma
;
Brachytherapy
;
Chemoradiotherapy
;
Disease-Free Survival
;
Drug Therapy
;
Humans
;
Hysterectomy
;
Lymph Nodes
;
Multivariate Analysis
;
Neoplasm Metastasis
;
Pelvis
;
Prognosis
;
Radiotherapy*
;
Recurrence
;
Retrospective Studies
;
Uterine Cervical Neoplasms*